News Sentiment

INAB sentiment intelligence

In8bio Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 55 Balanced news tone 53 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 1.33 Week of 17 Jul 2026
Weighted tone 55/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

78/100 classification confidence.

Company focus 44

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

+0.0% over one week, -7.0% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Enterprise value to EBIT forward of IN8bio, Inc. – FWB:6JH0

Market Reaction

Balanced read

53/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 78/100 classification
One-week reaction 0.0% Price digesting
Trend fit Trend inactive -7.0% over four weeks
Fair value -90.8% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 14
Neutral 37
Negative 2

Relevance

Why the article matched

Direct first
Direct company coverage 44
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
TradingView 15
Market source 9
GlobeNewswire 6
TradingKey 5
Stock Titan 3
AD HOC NEWS 3
dars.gov.et 3
simplywall.st 2

Event Lens

What the news is about

Classified themes
Market update 26
Earnings 22
Analyst action 2
Regulatory and legal 1
Balance sheet 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-53 of 53
AD HOC NEWS Direct company coverage

IN8bio Inc Stock (US45332Y1001): Analyst coverage and valuation in focus

IN8bio Inc, a clinical-stage biotechnology company focused on gamma-delta T cell therapies for cancer, is being evaluated by a niche group of Wall Street analysts and investors. Due to its pre-revenue status and early-stage pipeline, valuation is based on pipeline potential, tria

Tone
Neutral 50/100
Event
Analyst action
Published
15 Jun 2026 13:39
Source
AD HOC NEWS
AD HOC NEWS Direct company coverage

IN8bio Inc stock (US45332Y1001): Q1 2026 update keeps focus on gamma-delta T?cell pipeline

IN8bio Inc reported its Q1 2026 financial results, emphasizing progress in its gamma-delta T-cell oncology pipeline. The company, a clinical-stage biotechnology firm, focuses on developing immunotherapies for cancer, leveraging gamma-delta T cells to target tumors. The update hig

Tone
Positive 62/100
Event
Earnings
Published
08 Jun 2026 12:40
Source
AD HOC NEWS
Zacks Investment Research Direct company coverage

Should I buy IN8bio (INAB)

Tone
Positive 66/100
Event
Market update
Published
04 Jun 2026 07:00
Source
Zacks Investment Research